[A case of docetaxel-resistant breast cancer responsive to paclitaxel therapy].
Gan To Kagaku Ryoho
; 28(4): 511-4, 2001 Apr.
Article
in Ja
| MEDLINE
| ID: mdl-11329786
ABSTRACT
A 73-year-old woman underwent docetaxel therapy for lung metastasis from breast cancer after having received CAF therapy. Because of the progressive disease due to secondary resistance to docetaxel, the patient was given three courses of paclitaxel therapy (60 mg/m2, day 1, 8, 15 and 22, repeated every 6 weeks). The paclitaxel therapy brought about no adverse effects and a 51%-reduction in the size of the metastatic lung tumor (PR). Although the duration of the response to the paclitaxel therapy was limited to about one month due to progression of a brain metastasis, paclitaxel therapy may be effective against docetaxel-resistant breast cancer.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Paclitaxel
/
Taxoids
/
Antineoplastic Agents, Phytogenic
Limits:
Aged
/
Female
/
Humans
Language:
Ja
Journal:
Gan To Kagaku Ryoho
Year:
2001
Document type:
Article